Saint Savvas Oncology Hospital

At Saint Savvas Oncology Hospital in Athens, a large share of the clinical research focuses on neoplasms, especially breast cancer in both early and advanced stages. These studies are designed to test new treatment options, improve recurrence prevention, and compare emerging endocrine and targeted therapies with current standards of care.

• Advanced and metastatic breast cancer treatment
• ER-positive, HER2-negative disease management
• Recurrence prevention in early-stage breast neoplasms

The site’s work in this area reflects a strong interest in improving outcomes for patients with hormone receptor-driven disease and other hard-to-treat breast cancers.

Another major research focus is non-small cell lung cancer and small cell lung cancer, including rare mutation-driven subtypes. The trials aim to evaluate new immunotherapy, targeted therapy, and combination approaches that may help extend survival and better control advanced disease.

• NSCLC with KRAS G12C, EGFR, or RET alterations
• Small cell lung cancer in relapsed or limited-stage settings
• Testing treatments to improve survival and disease control

Research in this therapeutic area also includes studies for patients after surgery or chemoradiotherapy, showing a broad effort to refine treatment across different stages of lung cancer.

The site also contributes to studies in digestive system diseases, with a particular emphasis on gastric cancer, gastroesophageal junction cancer, and colorectal cancer. These trials are focused on assessing new combinations and targeted approaches that may improve response rates and overall survival.

• Advanced gastric and gastroesophageal junction cancer
• Metastatic colorectal cancer with specific genetic changes
• Evaluating new anti-cancer combinations for better treatment effectiveness

This area highlights the hospital’s role in exploring precision medicine approaches for difficult gastrointestinal tumors.

Clinical trials at Saint Savvas Oncology Hospital also include advanced prostate cancer, urothelial carcinoma, and other metastatic solid tumors. The research is aimed at improving disease control, delaying progression, and identifying better combinations for patients with limited treatment options.

• Metastatic castration-resistant prostate cancer
• Metastatic hormone-sensitive prostate cancer
• Locally advanced or metastatic urothelial carcinoma

These studies broaden the site’s oncology portfolio beyond breast and lung cancer, with a clear focus on advanced cancer care.

The hospital participates in research on multiple myeloma, including patients who have already received prior therapy. These trials are intended to evaluate treatment effectiveness and support better response monitoring in a blood cancer setting.

• Relapsed multiple myeloma
• Monitoring treatment response with improved diagnostic tools
• Assessing new combinations for patients after earlier therapy

This work shows that the site’s oncology program extends into selected hematologic malignancies as well as solid tumors.

Beyond cancer-directed studies, the research portfolio includes supportive care topics such as chemotherapy-induced thrombocytopenia and low back pain. These trials aim to improve symptom control, help patients stay on scheduled cancer treatment, and relieve pain more effectively.

• Chemotherapy-induced thrombocytopenia in patients with cancer
• Low back pain symptom relief
• Improving tolerance of ongoing cancer therapy

This mix of studies reflects a practical interest in both cancer treatment and the quality of care patients receive during therapy.

Although oncology dominates the research profile, the site also includes a study in primary biliary cholangitis, a chronic liver disease. This trial is focused on evaluating whether a new therapy can better control disease activity and related clinical outcomes.

• Primary biliary cholangitis
• Testing a treatment for long-term disease control
• Expanding research beyond cancer into selected chronic conditions

It adds a smaller but meaningful non-oncology dimension to the hospital’s clinical research activity.